奥扎格雷在急性冠脉综合征中抗血小板作用的研究

目的：通过对血小板活化指标血小板颗粒膜糖蛋白（CD62p）及血小板脂膜蛋白（CD61）与血浆假性血友病因子（vWF）的观测,探讨抗血小板药物奥扎格雷（Ozagrel）对急性冠脉综合征（ACS）患者血小板功能的影响。方法：应用流式细胞术（FCM）和酶联免疫吸附试验（ELISA）测定60例ACS患者应用奥扎格雷治疗前后静脉血CD62p,CD61和血浆vWF的表达水平,对两者在ACS时的水平进行对比分析。同时设20例健康体检者做对照组。结果：CD62p值：ACS患者的为（85.02±7.22）%,明显高于对照组（32.56±6.39）%（P〈0.05）,药物治疗后ACS组下降至（65.20±8.17）%（P〈0.05）,其水平变化与vWF、心绞痛和缺血ST-T改善一致;CD61表达量为（89.38±7.13）%,与正常组比较差异无显著性（P〉0.05）,药物干预治疗前、后比较,差异亦无显著性（P〉0.05）。结论：CD62p是血小板活化的敏感指标,且与vWF和临床症状改变一致。推测急性冠脉综合症患者应用奥扎格雷有进一步增强抗血小板的作用。

Effect of ozagrel on anti-platelet functions in patients with acute coronary syndrome

Objective： To observe the anti-platelet effects of Ozagrel in patients with acute coronary syndrome （ACS） . Methods： CD62p, CD61 used as platelet marks from whole blood samples were measured by FCM and vWF was measured by ELISA method in 60 patients with ACS and 20 healthy peoples taken as control group. Results： The amount of expression of CD62p was （85.02±7.22） % in ACS patients group and （32.56±6.39） % in control group, there was significant difference between ACS group and control group （P〈0. 05） . The amount of CD62p declined to （65.20±8.17）% after treated with Ozagrel （P〈0. 05） . There was also significant difference of CD62p in ACS group between before and after intervention of Ozagrel （P〈0. 05）. The amount change of CD62p in patients with ACS was relative to the improvement of angina pectoris and the changes of ST segments. However there was no difference of CD61 expression between ACS group and control group （P〉0. 05） . There was also no difference of CD61 before and after treatment of Ozagrel （P〉0. 05）. Conclusion： CD62p is a sensitive index of platelet activation in ACS patients and there is excellent relationship among CD62p and vWF and clinical symptoms.